Who Owns Artivion Company?

Artivion Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Artivion?

Artivion, Inc., formerly CryoLife, Inc., is a global medical device company with a history dating back to its founding in 1984. It specializes in innovative solutions for cardiac and vascular surgical procedures, with a particular focus on aortic conditions.

The company's evolution reflects a strategic shift, rebranding in January 2022 to better align with its expanded portfolio. Artivion's commitment to advancing cardiovascular health is evident in its diverse product offerings.

Artivion operates as a publicly traded entity, with its shares listed on the NYSE under the ticker symbol AORT. As of July 22, 2025, its market capitalization stood at approximately $1.43 billion. The company's global reach extends to over 100 countries, underscoring its significant presence in the medical device market. Its product range includes advanced solutions like Artivion BCG Matrix, alongside other critical cardiovascular technologies.

Artivion, Inc., originally established in 1984 as CryoLife, was founded by Steven Anderson and Robert McNally in Sarasota, Florida. Steven Anderson also took on the role of the company's first president and CEO upon its inception. While precise initial equity distributions are not publicly detailed, the company's early focus was on the cryopreservation of human heart valves and tissues for transplantation, driven by the founders' commitment to cardiovascular health solutions.

Founding Year and Location

Artivion was founded in 1984. Its initial operations began in Sarasota, Florida.

Founders

The company was established by Steven Anderson and Robert McNally. Steven Anderson served as the inaugural president and CEO.

Initial Business Focus

The company's early mission centered on the cryopreservation of human heart valves and tissues for transplant purposes.

Headquarters Relocation

The company later relocated its headquarters from Sarasota, Florida, to Kennesaw, Georgia, within the Atlanta metropolitan area.

Early Investment Details

Specifics regarding early angel investors or friends and family stakes during the company's inception are not widely documented in public records.

Founding Vision

The founders' initial vision was to address critical needs within cardiovascular health through innovative tissue preservation techniques.

The foundational work in tissue preservation by the founding team established the basis for Artivion's subsequent expansion and diversification into a wider array of medical devices. Understanding the Growth Strategy of Artivion provides further context on how this early focus evolved.

Artivion SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Artivion, Inc., formerly CryoLife, has seen its ownership evolve significantly since its 1993 IPO. Key acquisitions have reshaped its strategic direction and market presence, impacting its overall shareholder base and governance structure.

The current Artivion ownership structure is heavily weighted towards institutional investors, who collectively hold a substantial majority of the company's shares. This indicates a strong presence of large financial entities managing significant portions of the company's stock. As of July 22, 2025, Artivion's market capitalization was approximately $1.43 billion, with 47 million shares outstanding, traded under the ticker symbol 'AORT'.

Key Artivion Shareholders

Institutional investors dominate Artivion's shareholder base. These entities play a crucial role in the company's governance and strategic decisions.

• Wellington Management Group LLP holds 4.045% of Artivion stock.
• Next Century Growth Investors LLC owns 2.395%.
• Northern Trust Corp has a stake of 1.075%.
• Other significant holders include State Street Corp. and Silvercrest Asset Management Group, Inc.

Artivion's journey has been marked by strategic acquisitions that have broadened its product offerings and market reach. The acquisition of On-X Life Technologies in January 2016 for $130 million enhanced its mechanical heart valve portfolio. Subsequently, the €225 million acquisition of JOTEC GmbH in October 2017 strengthened its position in aortic and peripheral vascular diseases. The September 2020 acquisition of Ascyrus Medical further bolstered its stent graft technology. These moves have not only diversified revenue streams but also influenced the company's overall governance and strategic focus on aortic repair, reflecting a commitment to growth and innovation. Understanding the Mission, Vision & Core Values of Artivion provides further context to these strategic shifts.

Artivion PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current board of directors for Artivion, Inc. is instrumental in guiding the company's strategic direction and corporate governance. J. Patrick Mackin holds the positions of Chairman of the Board, President, and Chief Executive Officer, having been appointed CEO in September 2014 and Chairman in May 2015.

While specific equity holdings for all board members are not publicly detailed, some executives do possess direct ownership of company stock. As of May 27, 2025, SVP Jean F. Holloway owned 178,510 shares, and as of May 23, 2025, Director Anthony B. Semedo owned 33,059 shares. Artivion operates under a standard one-share-one-vote system, meaning each share of common stock grants its holder one vote on matters brought before shareholders. There are no indications of dual-class share structures that would concentrate voting power. Shareholders approved executive compensation and additional equity financing during the 2025 Annual Meeting, as detailed in the company's annual DEF 14A proxy statement, which also provides information on director nominees and proposals for shareholder action.

Understanding Artivion's Ownership Structure

Artivion's ownership structure is based on a straightforward one-share-one-vote principle. This ensures that voting power is directly proportional to the number of shares held by each shareholder.

• Each common stock share equals one vote.
• No dual-class share structures are in place.
• Shareholder approval is required for key corporate actions.
• Information on ownership is available in proxy statements.
• Understanding Artivion's Target Market of Artivion can provide context for its strategic decisions.

Artivion Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Artivion has been actively managing its capital structure and expanding its market presence. A significant recent development involved the repurchase of approximately $95 million of its Convertible Senior Notes due in 2025, converting them into common stock. This strategic move is expected to result in the issuance of around 4.1 million shares, reflecting the company's commitment to debt management.

Artivion's financial performance in the first quarter of 2025 showed robust growth, with total revenues reaching $99.0 million, marking a 2% increase on a GAAP basis and a 4% increase on a non-GAAP constant currency basis compared to the first quarter of 2024. This growth was primarily fueled by strong performances in its stent grafts, On-X, and BioGlue product lines. Looking ahead to the full year 2025, the company has raised its revenue guidance, now anticipating revenues between $423 million and $435 million, which represents an 11% to 14% growth on a constant currency basis compared to 2024. Furthermore, Artivion projects its adjusted EBITDA to increase by 18% to 28% for the full year 2025, with an expected range of $84 million to $91 million.

Institutional Ownership Trends

As of July 2025, institutional investors hold a significant portion of Artivion's stock, with hedge funds and other institutions owning 86.37%. This indicates a strong confidence from major financial entities in the company's future prospects.

Recent Institutional Activity

In the first quarter of 2025, Thornburg Investment Management Inc. acquired 132,672 shares, valued at approximately $3.26 million. Additionally, Legacy Advisors LLC initiated a new stake worth $28,000 during the same period.

Insider Transactions

Insider selling activity was observed in May 2025, with SVP Jean F. Holloway selling 8,748 shares for over $253,000 and Director Anthony B. Semedo selling 2,600 shares for over $74,000. These sales represent minor adjustments to their holdings.

Investor Engagement

The company actively participates in investor conferences, demonstrating its commitment to engaging with the financial community. This engagement underscores its focus on communicating its strategic direction and growth opportunities, as detailed in the Revenue Streams & Business Model of Artivion.

Artivion Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔